

# **Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2**

**An evaluation using the test-negative design**

**Guidance Document**

## CORRIGENDA

Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2. An evaluation using the test-negative design. Guidance document.

Document number: WHO/EURO:2021-2481-42237-58308.

These corrections have been incorporated into the electronic file on 09 July 2021.

- Page 6. The phrase “using existing SARI surveillance systems” was removed because it was redundant.
- Page 7. “See Section 4.4” was deleted
- Page 7. The phrase “VE of” was changed to “VE against.”
- Page 11. The reference in 3.12 was changed from Annex 2 to Annex 1.
- Page 11. In section 3.12, section references for “influenza and other viruses” and “vaccinations and antivirals” were removed.
- Page 11. In section 3.12, the functional status or proxy by residence type was changed to section 3.9.7
- Page 12. In section 3.12.3, the section reference for smoking history was removed

- Page 19. In section 3.13.4, Table 3, parentheses were added to the first row to indicate “interquartile range”
- Page 22. In section 4.1.2, the second-to-last sentence should read “which may increase their likelihood to be infected by SARS-CoV-2.”
- Page 18. In section 4.1.4, an “s” was added to the word “control.”
- Page 18. In section 4.1.4, “increase CVE” was changed to “decrease CVE” at the end of the first paragraph.
- Page 28. In Annex 2, “heart failure” was deleted the second time it appeared.
- Page 31. The word “numeric” was added in the same row as “residence.”
- Page 33. The second “Hypersensitivity pneumonitis due to organic dust” was removed
- Page 33. The Tuberculosis row was shaded in grey because it’s optional.
- Page 42. Section M changed to “Public Health and Social Measures.”
- Page 43. The reference 3.12.7 was changed to “3.12.6”
- Page 44. The following text was added: “as described in the main protocol” and the specific reference was deleted.

Document number: WHO/EURO:2021-2481-42237-58308

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition: Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2. An evaluation using the test-negative design: guidance Document. Copenhagen: WHO Regional Office for Europe; 2021”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. (<http://www.wipo.int/amc/en/mediation/rules/>)

**Suggested citation.** Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2. An evaluation using the test-negative design: guidance Document. Copenhagen: WHO Regional Office for Europe; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

## Contents

Acknowledgements .....	v
Abbreviations .....	vi
Executive Summary.....	vii
1. Background .....	1
2. Objectives.....	2
2.1 Primary objective	2
2.2 Secondary objectives	2
3. Methods .....	3
3.1 Harnessing existing SARI surveillance systems to estimate CVE	3
3.2 SARI surveillance population	3
3.3 Surveillance period for CVE analysis	3
3.4 Outcome	3
3.5 SARI Case definition	4
3.6 SARI patient identification – algorithm for patient inclusion	4
3.7 Laboratory methods	7
3.8 Vaccination history	8
3.9 Additional information to collect from SARI patients	8
3.10 Ethical considerations	10
3.11 Data	10
3.12 Information to be collected from SARI patients (See Annex 2)	11
3.13 Data analysis	14
4. Limitations.....	17
4.1 Potential biases	17
4.2 Representativeness of subjects	19
4.3 Community Engagement	19
5. Annexes.....	20
Annex 1. Questionnaire for SARI Patients	20
Annex 2. List of ICD-9 and ICD-10 codes for pre-existing chronic conditions	28
Annex 3. List of variables, definitions and coding; hospital-based COVID-19 vaccine effectiveness minimum dataset	31
Annex 4. Pooling Data	43
Annex 5. Additional information for pooled analysis	51
References .....	52

## Acknowledgements

The WHO Regional Office for Europe led the development of this document with Angie Rose (Epiconcept), Pernille Jorgensen, Mark Katz, and Richard Pebody (WHO Regional Office for Europe). The WHO Regional Office for Europe convened an ad-hoc expert review committee that provided strategic direction and direct inputs into the protocol. The WHO Regional Office for Europe would like to thank the following members of the review committee (in alphabetical order):

1. Nick Andrews, Public Health England, United Kingdom
2. Melissa Arvay, US Centers for Disease Control and Prevention, Atlanta, GA, USA
3. Sabrina Bacci, European Centre for Disease Prevention and Control, Stockholm, Sweden
4. Ed Belongia, Marshfield Clinic, Wisconsin, USA
5. Alessandro Cassini, World Health Organization, HQ, Geneva, Switzerland
6. Ben Cowling, Hong Kong School of Public Health, Hong Kong
7. Daniel Feikin, World Health Organization, HQ, Geneva, Switzerland
8. Wiebke Hellenbrand, Robert Koch Institute, Germany
9. Kari Johansen, European Centre for Disease Prevention and Control, Stockholm, Sweden
10. Esther Kissling, Epiconcept, Paris, France
11. Arnold Monto, University of Michigan School of Public Health, Michigan, USA
12. Alain Moren, Epiconcept, Paris, France
13. Francisco Nogareda, Pan American Health Organization, Washington DC, USA
14. Hanna Nohynek, THL, Helsinki, Finland
15. Pasi Penttinen, European Centre for Disease Prevention and Control, Stockholm, Sweden
16. Sheena Sullivan, Doherty Institute, Melbourne, Australia
17. Marta Valenciano, Epiconcept, Paris, France
18. Marc-Alain Widdowson, Institute of Tropical Medicine, Antwerp, Belgium

This publication has been supported by WHO Unity Studies, a global sero-epidemiological standardization initiative.

## Abbreviations

COVID-19	Coronavirus disease 2019
CVE	COVID-19 vaccine effectiveness
EEA	European Economic Area
ECDC	European Centre for Disease Prevention and Control
EU	European Union
GP	General practitioner
ICD	International classification of diseases
ILI	Influenza-like illness
I-MOVE	Influenza – Monitoring Vaccine Effectiveness in Europe
MS	Member States
OR	Odds ratio
RF	Risk factor
RT- PCR	Real-time polymerase chain reaction
SARI	Severe acute respiratory infection
SARS-CoV-2	Severe acute respiratory syndrome – coronavirus 2
VE	Vaccine effectiveness

## Executive Summary

Many critical questions remain about the effectiveness of COVID-19 vaccines in real-world settings. These questions can only be answered in post-introduction vaccine effectiveness studies.

This guidance document outlines an approach to leverage existing surveillance systems for Severe Acute Respiratory Infection (SARI) to estimate COVID-19 vaccine effectiveness (VE) in preventing SARI associated with laboratory-confirmed SARS-CoV-2. The approach uses the test-negative design to evaluate VE; cases are SARI patients who tested positive for SARS-CoV-2, and controls are SARI patients who tested negative for SARS-CoV-2.

As in current SARI surveillance, hospitalized patients with SARI at designated SARI surveillance hospitals can be enrolled if they meet the WHO case definition for SARI. A respiratory specimen should be collected from SARI patients within 48 hours of admission to the hospital. In addition, data can be collected about the patient's sociodemographic characteristics, history of acute illness, clinical course in hospital, and the COVID-19 vaccine history.

The document proposes that enhanced SARI surveillance to allow for VE estimates be implemented for a minimum of 6 months but ideally longer. The methods described in the guidance document are also appropriate for estimating influenza VE. The document also proposes that a pooled data analysis be conducted for the WHO/Europe region, which requires that SARI surveillance systems collect a minimum data set of similar variables.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23915](https://www.yunbaogao.cn/report/index/report?reportId=5_23915)

